Vanda Pharmaceuticals VNDA Revenue Breakdown

NASDAQ VNDA
$4.63 -0.18 (-3.74%)
At close: Oct 2, 2026 · 4:00 PM EDT
Annual revenue breakdowns for Vanda Pharmaceuticals, fiscal 2015 to 2025, as reported in its filings.
Annual history

Vanda Pharmaceuticals Revenue by Product & Service

Years FY 2015–2025
Lines 3
FY 2025 Total $216.11M

Fanapt® was Vanda Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $117.30M of $216.11M (54%).

Vanda Pharmaceuticals revenue by product and service, fiscal 2015 to 2025
Product and Service FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Hetlioz $159.66M $100.17M $76.68M $71.43M
Fanapt® $94.73M $90.87M $94.30M $117.30M
Ponvory® — $1.60M $27.80M $27.37M
Total $254.38M $192.64M $198.77M $216.11M
Totals include 1 discontinued line from earlier reporting.

Vanda Pharmaceuticals revenue by product and service: what the figures show

Vanda Pharmaceuticals brought in $216.11M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 8.7% from $198.77M in fiscal 2024. Fanapt® was the largest at $117.30M (54.3%), ahead of Hetlioz at $71.43M (33.1%) and Ponvory® at $27.37M (12.7%).

Compared with fiscal 2024, Fanapt® grew fastest, up 24.4% to $117.30M, while Hetlioz fell the most, down 6.8% to $71.43M.

Vanda Pharmaceuticals began breaking out Ponvory® in fiscal 2023, when it brought in $1.60M.

Questions

Vanda Pharmaceuticals Revenue Breakdown FAQ

How does Vanda Pharmaceuticals make money?

Vanda Pharmaceuticals (VNDA) reports its revenue by product and service. In fiscal 2025, Fanapt® was its largest product and service line, bringing in $117.30M (54.3% of the total), followed by Hetlioz at $71.43M (33.1%).

What is Vanda Pharmaceuticals' largest product and service line?

Fanapt® was Vanda Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $117.30M, or 54.3% of the $216.11M total across its three product and service lines.

Which Vanda Pharmaceuticals product and service line is growing the fastest?

Among Vanda Pharmaceuticals' product and service lines that make up at least 2% of revenue, Fanapt® grew fastest in fiscal 2025, up 24.4% from $94.30M to $117.30M.

Where does this revenue breakdown data come from?

Every figure comes from Vanda Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Vanda Pharmaceuticals gives it, and years follow its fiscal calendar.

How far back does Vanda Pharmaceuticals' revenue breakdown go?

Vanda Pharmaceuticals' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.